Physician profile
Blake D Hatfield
NPI 1811382062
$1,530.41
in general payments reported to CMS, 2019-2025
18 companies · $377 in 2025
The $377 reported for 2025 was more than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $13.19 · 2020: $135 · 2021: $409 · 2022: $451 · 2023: $19.71 · 2024: $126 · 2025: $377.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $523.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $522.59 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Gilead Sciences, INC. | $386.95 | 2020-2025 | |
| Merck Sharp & Dohme LLC | $288.32 | 2021-2025 | Pifeltro, Capvaxive, Dificid |
| Abbvie INC. | $248.83 | 2021-2024 | |
| Viiv Healthcare Company | $112.88 | 2020-2024 | Apretude |
| Janssen Pharmaceuticals, INC | $65.02 | 2021-2022 | |
| Lilly USA, LLC | $62.84 | 2020-2021 | |
| Pfizer INC. | $58.13 | 2021-2025 | |
| Novo Nordisk INC | $58.10 | 2021-2024 | Wegovy |
| Abbott Laboratories | $54.44 | 2021-2024 | Freestyle Libre 3 |
| Dexcom, INC. | $41.03 | 2022 | |
| Antares Pharma, INC. | $32.46 | 2021 | |
| Amarin Pharma, INC. | $24.60 | 2022 | |
| Amgen INC. | $19.28 | 2025 | Otezla, Repatha |
| Verity Pharmaceuticals INC. | $18.51 | 2025 | Tlando |
| Theratechnologies INC. | $17.30 | 2021 |
Show all 18 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astellas Pharma US INC | $15.35 | 2021 | |
| Teva Pharmaceuticals USA, INC. | $13.19 | 2019 | |
| Allergan, INC. | $13.18 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Blake Hatfield listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.